Jake Simson, PhD

Jake Simson is a Partner at RA Capital Management, where he works across public and private investments. RA Capital lists him as a board director for Bicara Therapeutics, Convergent Therapeutics, Janux Therapeutics, Outpace Bio, Septerna, Tyra Biosciences, and Vivace Bio. The firm also states that he previously covered solid tumor oncology landscapes. His doctoral research focused on clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. He holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University.